Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel

Fig. 1

Elevated expression of HER3 is frequently observed in TNBC clinical samples and cell lines and associates with poor clinical outcomes in TNBC patients. A, IHC assays were performed to examine HER3 protein expression in a tissue microarray (TMA) of TNBC specimens (n = 125). Representative images of negative (-), low (+), medium (++), and high (+++) staining intensity of HER3 expression were shown. The case number in each group was shown underneath. B, The heatmap showed HER3 mRNA expression in CCLE breast cancer cell lines (http://software.broadinstitute.org/morpheus). Red colors indicated TNBC cell lines. C, Analyses of overall survival (OS) or relapse-free survival (RFS) of basal-like breast cancer patients were performed using Kaplan-Meier Plotter (https://kmplot.com/analysis/). The expression levels of HER3 mRNA were determined in TCGA-curated basal-like breast cancer datasets and used for log rank tests to compare the survival curves of those with high (red) or low (black) HER3 expression

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us